Thursday, September 10, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical

View original at finance.yahoo.com
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical For Immediate Release Chicago, IL – December 30, 2025 – Today, Zacks Equity Research discusses Veracyte VCYT, IDEXX Laboratories IDXX and Intuitive Surgical ISRG…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Veracyte holds a Zacks Rank #1 (Strong Buy)

    80% confidence

  • Global AI in the healthcare market is projected to witness a CAGR of 44% from 2025 to 2032

    80% confidence

  • The Zacks Medical Instruments industry is trading at a forward 12-month P/E of 30.36X, compared with the broader industry's 21.29X and the S&P 500's 23.42X

    80% confidence

  • Global generative AI in the healthcare market is valued at $2.64 billion in 2025 and is expected to witness a CAGR of 35.2% through 2034

    80% confidence

  • Global growth is expected to remain at 3.2% in 2025 and 3.1% in 2026, below the pre-pandemic average of 3.7%

    80% confidence

  • Veracyte's 2025 EPS consensus estimate is $1.65, representing 38.7% growth from 2024

    80% confidence

  • IDEXX Laboratories' 2025 sales consensus estimate is $4.28 billion, representing 9.9% growth

    80% confidence

  • Veracyte's 2025 sales consensus estimate is $508.6 million, representing 14.1% growth from 2024

    80% confidence

  • IDEXX Laboratories' 2025 EPS consensus estimate is $12.93, representing 21.2% growth

    80% confidence

  • IDEXX Laboratories holds a Zacks Rank #2 (Buy)

    80% confidence

  • The application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 20.4% by 2034

    80% confidence

  • Intuitive Surgical's 2025 EPS consensus estimate is $8.65, representing 17.9% growth year-over-year

    80% confidence

  • The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence

  • The Medical Instruments industry's five-year P/E range has been as high as 40.76X, as low as 25.73X, with a median of 32.28X

    80% confidence

  • Overall MedTech M&A activity remained below historical norms, with only 46 announced deals through November 30, 2025

    80% confidence

  • Intuitive Surgical's 2025 sales consensus estimate is $9.92 billion, representing 18.7% growth from 2024

    80% confidence

  • Zacks top stock-picking strategies have averaged gains of +48.4%, +50.2%, and +56.7% per year since 2000, versus the S&P's +7.7% average annual gain

    80% confidence

  • MedTech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals

    80% confidence

  • The Zacks Medical Instruments industry carries a Zacks Industry Rank #161, placing it in the bottom 33% of 243 Zacks industries

    80% confidence

  • Global headline inflation is expected to decline to 4.2% in 2025 and to 3.7% in 2026

    80% confidence

  • Intuitive Surgical holds a Zacks Rank #2 (Buy)

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Boom Meets Valuation Jitters: Funding Surges While Bellwether Stocks Wobble
A dense wave of AI-sector funding (Socure, Stability AI, Emerald AI, Generalist AI, Gatik, Regent Craft and others closing rounds on the same day) and strong enterprise-automation earnings (UiPath raising full-year guidance) point to continued heavy capital deployment into AI infrastructure, fintech-adjacent AI, and agentic automation. Yet Palantir's stock fell even after winning the Army's high-profile TITAN contract, and commentary (e.g., the Alphabet bull case citing AI capex and regulatory risk) signals growing investor unease about whether current AI valuations and spending levels are sustainable.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts represent the same entity (JPMorgan Chase & Co.), same attribute (EPS), and same observation date (2025-12-31), which aligns with FY 2025 year-end reporting. Fact A explicitly states FY 2025 with EPS of 20.02 USD/share. Fact B has an unspecified fiscal period (N/A) but reports 4.63 USD, a significantly different value (4.3x lower). Given identical observation dates and the same metric, both facts appear intended to represent FY 2025 annual EPS. The conflicting values (20.02 vs 4.63) constitute a direct contradiction. The N/A period in Fact B suggests incomplete or corrupted metadata rather than legitimate time-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,278 source documents archived
Query this data → isubstrate.com
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical — Source | Via News | Via News